Recomendar CONGRESOS.NET Recibir congresos de categoría: Atención Primaria, Salud global,

 Recibir gratuitamente información de congresos


Su email:

    > Vaccine Delivery Systems for the Future

Vaccine Delivery Systems for the Future

17 May 2013The Stevenage Bioscience Catalyst, Stevenage, United Kingdom


 The Stevenage Bioscience Catalyst
Gunnels Wood Road
United Kingdom
Map and Directions

This conference provides a platform for researchers, physicians and enterprisers to discuss and learn about all the important breakthrough developments in vaccine delivery and on new therapeutics and know what the new trend of the vaccine (drug) delivery technologies is in future and how these technologies can be developed, realized and commercialized. It also provides scientist the opportunity to present their cutting-edge researches in the area of vaccination, drug delivery, gene delivery, immunotherapy and nanotechnology. Throughout the course of the 1-day conference, you will have the opportunity to both expanding the network and hear leaders from the pharmaceutical, academic and clinical communities.

This event is part of the 2013 Euroscicon BioTherapeutics Week,
to find out more see

This event has CPD accreditation

Meeting chair: Dr Lan Chen, Department of Chemical Engineering and Biotechnology University of Cambridge

Who Should Attend
Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research

Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students

Talks include

Non-Replicating Viral Vaccines and Novel Antigen Delivery System
Professor Polly Roy, London School of Hygiene & Tropical Medicine, UK

Development of Novel Antibody-Inducing Vaccines against Human Malaria
Dr Simon Draper, The Jenner Institute, University of Oxford
The human malaria parasite Plasmodium falciparum continues to exert a huge burden on global public health, whilst the development of a highly efficacious vaccine has proved extremely challenging. The disease-causing blood-stage of the parasite’s life-cycle is known to be susceptible to antibodies. However, the field has faced significant hurdles in translating this knowledge into efficacious clinical subunit vaccine products. This talk will focus on the development of new approaches to vaccine antigen identification and delivery in the context of human malaria, and will summarise experience to date of these new strategies in Phase I/IIa clinical trials.

Talk title to be confirmed
Dr Amin Hajitou, Imperial College Faculty of Medicine Division of Brain Sciences, Hammersmith Hospital, United Kingdom

Multifunctional Nanoparticle - new platform for vaccine delivery
Dr Lan Chen, Department of Chemical Engineering and Biotechnology University of Cambridge
Great advances have been made in the past decades on the development of vaccine delivery but the dilemma between immunogenicity, safety and tolerability has remained a major challenge and not been well overcome. Therefore, it needs to develop smarter delivery solutions to overcome this weakness. A smart drug delivery system is the system that can act accurately only in targeted tissue and make diagnosis and provide therapy during the same time. To achieve these functions, a custom made nano-platform will firstly be built. Then, various therapy cargos will be loaded onto the platform according to requirement, where the cargos are not only chemical substances but any active components, like fluorescent tags, antibodies, peptides and DNA. Eventually, healthcare delivery at low cost, low side-effect, high efficacy and long-lasting manners will be achieved.

Talk to be confirmed
Dr Wing Man Lau, School of Pharmacy, University of Reading, UK

Approaches to T cell vaccines for HIV
Dr Steven Patterson, Imperial College at Chelsea and Westminster Hospital, UK
An effective HIV vaccine is thought to require T cell responses. T cell immune responses induced by acute infection or a vaccine are usually limited to recognition of a small number of immunodominant or subdominant epitopes. This presents a major hurdle in the development of a T cell vaccine for HIV since a high mutation rate enables the virus to quickly escape immune recognition. Vaccine strategies designed to induce responses to multiple T cell epitopes and overcome the problem of immune escape will be described.

About the Speakers

Polly Roy began her education in Calcutta, India but won a fellowship to New York University for her PhD under the supervision of the renowned molecular biologist, Sol Spiegleman. A 3-year postdoctoral position in virology at the Waksman Institute, Rutgers University, followed after which she joined the University of Alabama at Birmingham to establish her own virology research group where she became a full Professor in 1986. In 1987 she received a senior International Fogarty fellowship to study at the University of Oxford where she gradually established a UK-based research group. In 1997, she became Professor at the University of Oxford and in 2001 took the chair of Virology at the London School of Hygiene and Tropical Medicine. Her studies have contributed in many areas of virology, notably virus structure, assembly, RNA replication and vaccine development. Roy was the first to demonstrate the assembly of virus-like particles (VLPs), a technology which has been applied since to many other viruses including for successful vaccine development for Human Papillomavirus, Influenza and SARS. Recently Roy pioneered the synthesis of infectious virus solely from synthetic genes, a major achievement which opens a new window of opportunity for the development of new therapies in the longer term. She has supervised over 140 post-doctoral and post-graduate researchers, published over 300 research papers and has served on various international scientific organizations, committees and boards. She has organized several highly successful international conferences, particularly on the subject of virus assembly and in 2006 was elected a Fellow of the Academy of Medical Sciences. This year Roy has received a Gold Medal for her contribution to science and technology from the Indian Prime Minister during the Annual Indian Science Congress (2012), along with three Nobel laureates. She is also one of the three BBSRC Scientific Innovators of the year.

Simon Draper’s group is based at the Jenner Institute, University of Oxford. His research interests include studies of vaccine-induced malaria immunity as well as the optimisation of antibody induction by subunit vaccines against blood-stage malaria infection. In recent years, his group has developed novel vaccines targeting blood-stage antigens from the human malaria parasite Plasmodium falciparum, and these have been translated into Phase I/IIa clinical trials. His group are also focusing on the identification of new antigen combinations that may prove to be more successful in inducing protective efficacy against malaria by subunit vaccination in humans.
Steven Patterson is based in the Immunology Department at Imperial College’s Chelsea and Westminster Campus where the main research focus of department is HIV. His main research interests are in HIV pathogenesis, vaccines and human dendritic cell biology. Since the mid 1980s his group have investigated the role of dendritic cells in HIV pathogenesis and but in the last six years they have been funded by the Bill and Melinda Gates Foundation to develop a T cell vaccine for HIV that will overcome the problem of virus escape from immune recognition.

Keywords: Malaria; Vaccine; Antibody; Immunology,Vaccine delivery; Immunotherapy; Nanoparticles, Drug-delivery; Gene-Delivery, HIV, vaccine, T cells

Registration Web Site:

Otros congresos relacionados con:

Otros congresos

Categorías (0 congresos en total)

2020    2021    
2022    2023    

Publicitar congreso

No dudes en publicitar congresos gratuitamente en CONGRESOS.NET, envíanos los datos del congreso.

Directorio de proveedores

Donde encontrarás Organizadores de Congresos, OPCs, Hoteles, Agencias de Azafatas... etc.

© 2012 CONGRESOS.NET      Recomendar  -  Aviso legal  -  Mapa web  -  Contacto
Desarrollado por